Predicting allopurinol response in patients with gout

被引:43
|
作者
Wright, Daniel F. B. [1 ]
Duffull, Stephen B. [1 ]
Merriman, Tony R. [2 ]
Dalbeth, Nicola [3 ]
Barclay, Murray L. [4 ,5 ]
Stamp, Lisa K. [4 ]
机构
[1] Univ Otago, Sch Pharm, POB 56, Dunedin 9054, New Zealand
[2] Univ Otago, Dept Biochem, Dunedin 9054, New Zealand
[3] Univ Auckland, Dept Med, Auckland 1, New Zealand
[4] Univ Otago, Dept Med, Christchurch, New Zealand
[5] Christchurch Hosp, Dept Clin Pharmacol, Christchurch, New Zealand
关键词
allopurinol; gout; nonmem; pharmacokinetic-pharmacodynamics; CONTROL SAMPLE SETS; SERUM URIC-ACID; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; VS; SEQUENTIAL-ANALYSIS; HYPERSENSITIVITY SYNDROME; CREATININE CLEARANCE; PLASMA OXYPURINOL; ADVERSE-REACTIONS; HEALTHY-SUBJECTS;
D O I
10.1111/bcp.12799
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AimsThe primary aim of this research was to predict the allopurinol maintenance doses required to achieve the target plasma urate of 0.36mmoll(-1). MethodsA population analysis was conducted in nonmem using oxypurinol and urate plasma concentrations from 133 gout patients. Maintenance dose predictions to achieve the recommended plasma urate target were generated. ResultsThe urate response was best described by a direct effects model. Renal function, diuretic use and body size were found to be significant covariates. Dose requirements increased approximately 2-fold over a 3-fold range of total body weight and were 1.25-2 fold higher in those taking diuretics. Renal function had only a modest impact on dose requirements. ConclusionsContrary to current guidelines, the model predicted that allopurinol dose requirements were determined primarily by differences in body size and diuretic use. A revised guide to the likely allopurinol doses to achieve the target plasma urate concentration is proposed.
引用
收藏
页码:277 / 289
页数:13
相关论文
共 50 条
  • [31] The Efficacy and Tolerability of Allopurinol Dose Escalation in Patients with Gout
    Radak-Perovic, Marija
    Zlatkovic-Svenda, Mirjana
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2013, 141 (5-6) : 333 - 336
  • [32] METABOLIC AND THERAPEUTIC EFFECTS OF ALLOPURINOL IN PATIENTS WITH LEUKEMIA AND GOUT
    VOGLER, WR
    BAIN, JA
    HUGULEY, CM
    PALMER, HG
    LOWREY, ME
    AMERICAN JOURNAL OF MEDICINE, 1966, 40 (04): : 548 - &
  • [33] Treatment of tophaceous gout in patients intolerant to allopurinol.
    Grahame, R
    Simmonds, A
    McBride, M
    Marsh, F
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S151 - S151
  • [34] Adherence and Persistence to Allopurinol among Hypertensive Patients with Gout
    Perreault, Sylvie
    Nuevo, Javier
    Baumgartner, Scott
    Morlock, Rob
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 500 - 501
  • [35] Current management of gout in patients unresponsive or allergic to allopurinol
    Bardin, T
    JOINT BONE SPINE, 2004, 71 (06) : 481 - 485
  • [36] ADHERENCE AND PERSISTENCE TO ALLOPURINOL AMONG HYPERTENSIVE PATIENTS WITH GOUT
    Perreault, S.
    Nuevo, J.
    Baumgartner, S.
    Morlock, R.
    VALUE IN HEALTH, 2015, 18 (07) : A655 - A655
  • [37] THE EFFECT OF BENZBROMARONE ON ALLOPURINOL OXYPURINOL KINETICS IN PATIENTS WITH GOUT
    MULLER, FO
    SCHALL, R
    GROENEWOUD, G
    HUNDT, HKL
    VANDERMERWE, JC
    VANDYK, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (01) : 69 - 72
  • [38] EFFECT OF ALLOPURINOL ON URINARY AMMONIA EXCRETION IN PATIENTS WITH GOUT
    VOGLER, WR
    DRANE, JW
    METABOLISM, 1969, 18 (06): : 519 - +
  • [39] 'Treat-to-target' with allopurinol is feasible in patients with gout
    Shreeya Nanda
    Nature Reviews Rheumatology, 2011, 7 (1) : 3 - 3
  • [40] ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout
    Stamp, Lisa K.
    Wallace, Mary
    Merriman, Tony R.
    Phipps-Green, Amanda
    Topless, Ruth
    Drake, Jill
    Tan, Paul
    Dalbeth, Nicola
    Roberts, Rebecca
    ARTHRITIS & RHEUMATOLOGY, 2015, 67